Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD MarketGlobeNewsWire • 05/17/23
Opthea To Participate in Fireside Chat at Oppenheimer's 33rd Annual Healthcare ConferenceGlobeNewsWire • 03/06/23
Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal OphthalmologyGlobeNewsWire • 02/13/23
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MDGlobeNewsWire • 12/12/22
Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial OfficerGlobeNewsWire • 10/24/22
Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual ConferenceGlobeNewsWire • 08/16/22
Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMDGlobeNewsWire • 08/15/22
Optiva Inc. (RKNEF) CEO John Giere on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022GlobeNewsWire • 05/05/22